ASLAN PHARMACEU/ADR (NASDAQ:ASLN)’s stock price rose 36.1% during mid-day trading on Monday . The company traded as high as $8.18 and last traded at $5.20, approximately 15,433,472 shares traded hands during mid-day trading. An increase of 5,303% from the average daily volume of 285,622 shares. The stock had previously closed at $3.82.

Several research firms have commented on ASLN. BTIG Research lowered ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of ASLAN PHARMACEU/ADR in a report on Monday, November 25th. Zacks Investment Research upgraded shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 target price for the company in a research note on Monday, November 4th. Finally, Piper Jaffray Companies raised shares of ASLAN PHARMACEU/ADR from a “neutral” rating to an “overweight” rating and set a $8.00 price target on the stock in a report on Monday. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $4.00.

The company has a market cap of $87.50 million, a price-to-earnings ratio of -1.95 and a beta of 3.31. The company has a current ratio of 1.88, a quick ratio of 3.80 and a debt-to-equity ratio of 1.12. The business has a fifty day moving average of $1.70 and a two-hundred day moving average of $2.47.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.19. On average, research analysts forecast that ASLAN PHARMACEU/ADR will post -0.69 EPS for the current fiscal year.

A hedge fund recently raised its stake in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC increased its stake in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,100 shares of the company’s stock after acquiring an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned approximately 0.06% of ASLAN PHARMACEU/ADR worth $33,000 at the end of the most recent reporting period. Institutional investors own 7.12% of the company’s stock.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

Recommended Story: Return On Assets

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.